United States Patent and Trademark Office. Types of Vaccines and Patentability Considerations. Christina Chan Supervisory Primary Examiner Art Unit 1644 Phone: 571-272-0841 E-mail: email@example.com. Acquisition Of Passive And Active Immunity. Type Acquired through
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
United States Patent and
Types of Vaccines andPatentability Considerations
Supervisory Primary Examiner
Art Unit 1644
Humanized monoclonal antibody
Purified microbial macromolecules
Cloned microbial antigens
Expressed as recombinant protein
As cloned DNA alone or in virus vectors
5th Ed. 2003, Page 416
e.g. Therapeutic vaccine for HPV – associated cervical carcinoma.
- humoral response
- cell-mediated response
- Vaccine induces protective primary
immune response but fails to induce the formation of memory cells.
- incubation period of pathogens.
e.g. – Smallpox vaccine - Typhoid Vaccine
- Measles vaccine - Polio (Sabin) vaccine
e.g. – Salk injectable poliomyelitis vaccine (IPV)
- Hepatitis A vaccine
- Influenza vaccine
- Rabies vaccine
- Anthrax vaccine
- Cholera vaccine
Characteristic Attenuated vaccine Inactivated vaccine
Production Selection for avirulent organisms: Virulent pathogen is inactivated by
virulent pathogen is grown under chemicals or irradiation with gamma-rays
adverse culture conditions or
prolonged passage of a virulent
human pathogen through different hosts
Booster requirement Generally requires only a single booster Requires multiple boosters
Relative stability Less stable More stable (advantageous for Third
World countries where refrigeration is limited)
Type of immunity induced Produces humoral and cell-mediated Produces mainly humoral immunity
Reversion tendency May revert to virulent form Cannot revert to virulent form
4th Ed. 2000, page 455
e.g. – Pneumovax 23 (23 distinct capsular polysaccharides)
e.g. Tetanus (inactivated exotoxin)
e.g. – Hepatitis B surface antigen vaccine
Recombinant – Vector Vaccines
e.g. - Vaccinia virus
Synthetic Peptide Vaccines
Multivalent Subunit Vaccines
- Current state of the art.
2. A vaccine comprising the peptide of claim 1 and a pharmaceutically acceptable carrier.
3. A method of inducing an immune response in a host comprising administering to the host a composition comprising the peptide of claim 1 and a carrier.
Claim 3. A method of inducing an immune response in a host comprising administering to the host a composition comprising the peptide of claim 1 and a carrier.
Claim 1. A vaccine comprising an isolated protein comprising SEQ ID NO:3.Claim 2. A vaccine comprising a variant of the protein of claim 1
Claim 1. A vaccine comprising an isolated protein comprising SEQ ID NO:3.Claim 2. A vaccine comprising a variant of the protein of claim 1.
- Composition is prevented from being used as a vaccine.
- Reference does not enable how to make the claimed composition.
Supervisory Primary Examiner
At Unit 1644